These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 17703504)

  • 1. Determinants of skin sensitisation potential.
    Roberts DW; Aptula AO
    J Appl Toxicol; 2008 Apr; 28(3):377-87. PubMed ID: 17703504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical reactivity indices and mechanism-based read-across for non-animal based assessment of skin sensitisation potential.
    Roberts DW; Aptula AO; Patlewicz G; Pease C
    J Appl Toxicol; 2008 May; 28(4):443-54. PubMed ID: 17703503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of an integrated project (Sens-it-iv) to develop in vitro tests to assess sensitisation.
    Rovida C; Basketter D; Casati S; de Silva O; Hermans H; Kimber I; Manou I; Weltzien HU; Roggen E
    Altern Lab Anim; 2007 Jun; 35(3):317-22. PubMed ID: 17650950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applying the skin sensitisation adverse outcome pathway (AOP) to quantitative risk assessment.
    Maxwell G; MacKay C; Cubberley R; Davies M; Gellatly N; Glavin S; Gouin T; Jacquoilleot S; Moore C; Pendlington R; Saib O; Sheffield D; Stark R; Summerfield V
    Toxicol In Vitro; 2014 Feb; 28(1):8-12. PubMed ID: 24184331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guiding principles for the implementation of non-animal safety assessment approaches for cosmetics: skin sensitisation.
    Goebel C; Aeby P; Ade N; Alépée N; Aptula A; Araki D; Dufour E; Gilmour N; Hibatallah J; Keller D; Kern P; Kirst A; Marrec-Fairley M; Maxwell G; Rowland J; Safford B; Schellauf F; Schepky A; Seaman C; Teichert T; Tessier N; Teissier S; Weltzien HU; Winkler P; Scheel J
    Regul Toxicol Pharmacol; 2012 Jun; 63(1):40-52. PubMed ID: 22374415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An integrated decision-tree testing strategy for skin sensitisation with respect to the requirements of the EU REACH legislation.
    Grindon C; Combes R; Cronin MT; Roberts DW; Garrod JF
    Altern Lab Anim; 2008 Oct; 36 Suppl 1():75-89. PubMed ID: 19025333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allergic contact dermatitis: is the reactive chemistry of skin sensitizers the whole story?
    Basketter DA; Kimber I
    Contact Dermatitis; 2013 Apr; 68(4):244-5. PubMed ID: 23510345
    [No Abstract]   [Full Text] [Related]  

  • 8. Allergic contact dermatitis: is the reactive chemistry of skin sensitizers the whole story? A response.
    Roberts DW
    Contact Dermatitis; 2013 Apr; 68(4):245-9. PubMed ID: 23510346
    [No Abstract]   [Full Text] [Related]  

  • 9. A future approach to measuring relative skin sensitising potency: a proposal.
    Jowsey IR; Basketter DA; Westmoreland C; Kimber I
    J Appl Toxicol; 2006; 26(4):341-50. PubMed ID: 16773645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consideration of criteria required for assignment of a (skin) sensitiser a substance of very high concern (SVHC) under the REACH regulation.
    Basketter D; Kimber I
    Regul Toxicol Pharmacol; 2014 Aug; 69(3):524-8. PubMed ID: 24893346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal Langerhans cell migration and sensitisation to chemical allergens.
    Cumberbatch M; Dearman RJ; Griffiths CE; Kimber I
    APMIS; 2003; 111(7-8):797-804. PubMed ID: 12974781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skin sensitisation: the Colipa strategy for developing and evaluating non-animal test methods for risk assessment.
    Maxwell G; Aeby P; Ashikaga T; Bessou-Touya S; Diembeck W; Gerberick F; Kern P; Marrec-Fairley M; Ovigne JM; Sakaguchi H; Schroeder K; Tailhardat M; Teissier S; Winkler P
    ALTEX; 2011; 28(1):50-5. PubMed ID: 21311850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computer models versus reality: how well do in silico models currently predict the sensitization potential of a substance.
    Teubner W; Mehling A; Schuster PX; Guth K; Worth A; Burton J; van Ravenzwaay B; Landsiedel R
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):468-85. PubMed ID: 24090701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refinement of the Dermal Sensitisation Threshold (DST) approach using a larger dataset and incorporating mechanistic chemistry domains.
    Safford RJ; Aptula AO; Gilmour N
    Regul Toxicol Pharmacol; 2011 Jul; 60(2):218-24. PubMed ID: 21447365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of a systems biology approach to skin allergy risk assessment.
    Maxwell G; Mackay C
    Altern Lab Anim; 2008 Nov; 36(5):521-56. PubMed ID: 19025322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of contact allergens with dendritic cells: opportunities and challenges for the development of novel approaches to hazard assessment.
    Ryan CA; Gerberick GF; Gildea LA; Hulette BC; Betts CJ; Cumberbatch M; Dearman RJ; Kimber I
    Toxicol Sci; 2005 Nov; 88(1):4-11. PubMed ID: 16014741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An in vitro method for detecting chemical sensitization using human reconstructed skin models and its applicability to cosmetic, pharmaceutical, and medical device safety testing.
    McKim JM; Keller DJ; Gorski JR
    Cutan Ocul Toxicol; 2012 Dec; 31(4):292-305. PubMed ID: 22494060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Principles for identification of High Potency Category Chemicals for which the Dermal Sensitisation Threshold (DST) approach should not be applied.
    Roberts DW; Api AM; Safford RJ; Lalko JF
    Regul Toxicol Pharmacol; 2015 Aug; 72(3):683-93. PubMed ID: 25765509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The OSIRIS Weight of Evidence approach: ITS for skin sensitisation.
    Rorije E; Aldenberg T; Buist H; Kroese D; Schüürmann G
    Regul Toxicol Pharmacol; 2013 Nov; 67(2):146-56. PubMed ID: 23792263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting skin sensitization potential and inter-laboratory reproducibility of a human Cell Line Activation Test (h-CLAT) in the European Cosmetics Association (COLIPA) ring trials.
    Sakaguchi H; Ryan C; Ovigne JM; Schroeder KR; Ashikaga T
    Toxicol In Vitro; 2010 Sep; 24(6):1810-20. PubMed ID: 20510347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.